Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 9/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | NAT1 | P18440 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066619 | 1.00 | PTP4A3 (0.68) | PTP4A3PTPN1CA2GSK3BNAT1 | |
| SCHEMBL10090313 | 1.00 | PTP4A3 (0.68) | PTP4A3PTPN1CA2GSK3BNAT1 | |
| SCHEMBL2066455 | 0.93 | PTP4A3 (0.74) | PTP4A3PTPN1CA2GSK3B | |
| SCHEMBL2066452 | 0.93 | PTP4A3 (0.74) | PTP4A3PTPN1CA2GSK3B | |
| SCHEMBL2065351 | 0.90 | PTP4A3 (0.62) | PTP4A3PTPN1CA2GSK3BNAT1 | |
| SCHEMBL2065349 | 0.90 | PTP4A3 (0.62) | PTP4A3PTPN1CA2GSK3BNAT1 | |
| SCHEMBL2064963 | 0.87 | PTP4A3 (0.61) | PTP4A3PTPN1CA2GSK3B | |
| SCHEMBL2065513 | 0.87 | PTP4A3 (0.61) | PTP4A3PTPN1CA2GSK3BMEN1 | |
| SCHEMBL2065515 | 0.87 | PTP4A3 (0.61) | PTP4A3PTPN1CA2GSK3BMEN1 | |
| SCHEMBL2064964 | 0.87 | PTP4A3 (0.61) | PTP4A3PTPN1CA2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | claimed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | claimed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | PTP4A3 28/4885PTPN1 26/4885CA2 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.